469 related articles for article (PubMed ID: 33593877)
21. Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors.
Diamanti P; Ede BC; Dace PE; Barendt WJ; Cox CV; Hancock JP; Moppett JP; Blair A
Br J Haematol; 2021 Feb; 192(3):577-588. PubMed ID: 32452017
[TBL] [Abstract][Full Text] [Related]
22. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
DiNardo CD; Lachowiez CA; Takahashi K; Loghavi S; Xiao L; Kadia T; Daver N; Adeoti M; Short NJ; Sasaki K; Wang S; Borthakur G; Issa G; Maiti A; Alvarado Y; Pemmaraju N; Montalban Bravo G; Masarova L; Yilmaz M; Jain N; Andreeff M; Jabbour E; Garcia-Manero G; Kornblau S; Ravandi F; Konopleva MY; Kantarjian HM
J Clin Oncol; 2021 Sep; 39(25):2768-2778. PubMed ID: 34043428
[TBL] [Abstract][Full Text] [Related]
23. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
de Vos S; Swinnen LJ; Wang D; Reid E; Fowler N; Cordero J; Dunbar M; Enschede SH; Nolan C; Petrich AM; Ross JA; Salem AH; Verdugo M; Agarwal S; Zhou L; Kozloff M; Nastoupil LJ; Flowers CR
Ann Oncol; 2018 Sep; 29(9):1932-1938. PubMed ID: 30060083
[TBL] [Abstract][Full Text] [Related]
24. Real world results of venetoclax combined with hypomethylating agents in relapsed/refractory AML.
Ucar MA; Ozet G; Koyuncu MB; Sonmez M; Akidan O; Ayli M; Yildirim M; Pehlivan M; Akkurd DM; Sahin H; Guvenc B; Okan V; Tiftik EN; Akdeniz A; Dincyurek HD; Gunes AK; Dagdas S; Acar HI; Ucar HK; Tombak A
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6557-6565. PubMed ID: 34787859
[TBL] [Abstract][Full Text] [Related]
25. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia.
Short NJ; Jabbour E; Jain N; Senapati J; Nasr L; Haddad FG; Li Z; Hsiao YC; Yang JJ; Pemmaraju N; Ohanian M; Wierda WG; Montalban-Bravo G; Borthakur G; Han L; Xiao L; Huang X; Abramova R; Zhao M; Garris R; Konopleva M; Ravandi F; Kantarjian H
Blood Adv; 2024 Feb; 8(4):909-915. PubMed ID: 38207208
[TBL] [Abstract][Full Text] [Related]
26. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF
N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348
[TBL] [Abstract][Full Text] [Related]
27. A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Gemici A; Ozkalemkas F; Dogu MH; Tekinalp A; Alacacioglu I; Guney T; Ince I; Geduk A; Cagliyan GA; Maral S; Serin I; Gunduz E; Karakus V; Bekoz HS; Eren R; Pinar IE; Gunes AK; Sargın FD; Sevindik OG
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e686-e692. PubMed ID: 34059487
[TBL] [Abstract][Full Text] [Related]
28. Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.
Zhou Z; Zhang L; Wang X; Li X; Li L; Fu X; Zhang X; Li Z; Sun Z; Zhang M
Ann Hematol; 2021 Jun; 100(6):1509-1516. PubMed ID: 33900450
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.
Konopleva M; Pollyea DA; Potluri J; Chyla B; Hogdal L; Busman T; McKeegan E; Salem AH; Zhu M; Ricker JL; Blum W; DiNardo CD; Kadia T; Dunbar M; Kirby R; Falotico N; Leverson J; Humerickhouse R; Mabry M; Stone R; Kantarjian H; Letai A
Cancer Discov; 2016 Oct; 6(10):1106-1117. PubMed ID: 27520294
[TBL] [Abstract][Full Text] [Related]
30. [Clinical efficacy and safety of venetoclax combined with multidrug chemotherapy in the treatment of 15 patients with relapsed or refractory early T-cell precursor acute lymphoblastic leukemia].
Kong JY; Zong LH; Pu Y; Liu Y; Kong X; Li MY; Zhang J; Song BQ; Xue SL; Tang XW; Qiu HY; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):649-653. PubMed ID: 37803838
[No Abstract] [Full Text] [Related]
31. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies.
Roberts AW; Advani RH; Kahl BS; Persky D; Sweetenham JW; Carney DA; Yang J; Busman TB; Enschede SH; Humerickhouse RA; Seymour JF
Br J Haematol; 2015 Sep; 170(5):669-78. PubMed ID: 25942994
[TBL] [Abstract][Full Text] [Related]
32. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
Roberts AW; Seymour JF; Brown JR; Wierda WG; Kipps TJ; Khaw SL; Carney DA; He SZ; Huang DC; Xiong H; Cui Y; Busman TA; McKeegan EM; Krivoshik AP; Enschede SH; Humerickhouse R
J Clin Oncol; 2012 Feb; 30(5):488-96. PubMed ID: 22184378
[TBL] [Abstract][Full Text] [Related]
33. Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.
Secilmis S; Sinan Dal M; Kizil Cakar M; Merdin A; Ahu Baysal N; Altuntas F
J BUON; 2021; 26(5):2026-2032. PubMed ID: 34761613
[TBL] [Abstract][Full Text] [Related]
34. Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma.
Baig MU; Rytting M; Roth M; Morani AC; Nunez C; Lin P; Cuglievan B
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e991-e996. PubMed ID: 33480649
[TBL] [Abstract][Full Text] [Related]
35. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Wang M; Ramchandren R; Chen R; Karlin L; Chong G; Jurczak W; Wu KL; Bishton M; Collins GP; Eliadis P; Peyrade F; Lee Y; Eckert K; Neuenburg JK; Tam CS
J Hematol Oncol; 2021 Oct; 14(1):179. PubMed ID: 34717692
[TBL] [Abstract][Full Text] [Related]
36. New drugs approved for acute myeloid leukaemia in 2018.
Kucukyurt S; Eskazan AE
Br J Clin Pharmacol; 2019 Dec; 85(12):2689-2693. PubMed ID: 31469910
[TBL] [Abstract][Full Text] [Related]
37. Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2.
Morimoto Y; Takada K; Takeuchi O; Watanabe K; Hirohara M; Hamamoto T; Masuda Y
Mol Cell Biochem; 2020 Sep; 472(1-2):187-198. PubMed ID: 32567031
[TBL] [Abstract][Full Text] [Related]
38. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
Abuelgasim KA; Alherz N; Alhejazi A; Damlaj M
J Med Case Rep; 2020 Apr; 14(1):54. PubMed ID: 32321588
[TBL] [Abstract][Full Text] [Related]
39. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Davids MS; Roberts AW; Seymour JF; Pagel JM; Kahl BS; Wierda WG; Puvvada S; Kipps TJ; Anderson MA; Salem AH; Dunbar M; Zhu M; Peale F; Ross JA; Gressick L; Desai M; Kim SY; Verdugo M; Humerickhouse RA; Gordon GB; Gerecitano JF
J Clin Oncol; 2017 Mar; 35(8):826-833. PubMed ID: 28095146
[TBL] [Abstract][Full Text] [Related]
40. The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia.
Aumann S; Shaulov A; Haran A; Gross Even-Zohar N; Vainstein V; Nachmias B
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
